Core Viewpoint - Meihua Medical (301363) reported a slight decline in stock price and mixed financial results for Q3 2025, indicating growth in revenue but a significant drop in net profit year-to-date. Financial Performance - For Q3 2025, the company achieved operating revenue of 461,657,375.39 yuan, a year-on-year increase of 2.56% [1] - Year-to-date operating revenue reached 1,194,474,058.15 yuan, reflecting a growth of 3.28% compared to the same period last year [1] - The net profit attributable to shareholders for Q3 was 93,900,188.71 yuan, up 5.89% year-on-year, but down 19.25% year-to-date at 208,202,331.16 yuan [1][2] - The net profit excluding non-recurring gains and losses for Q3 was 92,706,846.77 yuan, a 9.56% increase year-on-year, while year-to-date it was 203,344,046.58 yuan, down 17.85% [1][2] Cash Flow and Earnings - The net cash flow from operating activities year-to-date was 221,973,418.65 yuan, a decrease of 26.43% compared to the previous year [2] - Basic earnings per share for Q3 were 0.17 yuan, a 13.33% increase year-on-year, but year-to-date it was 0.37 yuan, down 17.78% [2] - The weighted average return on equity year-to-date was 5.79%, a decline of 2.07 percentage points from the previous year [2] Asset and Equity Position - As of the end of the reporting period, total assets amounted to 4,179,497,349.18 yuan, an increase of 6.58% from the previous year-end [2] - The equity attributable to shareholders was 3,701,969,775.59 yuan, up 6.39% from the previous year-end [2] - The total number of common shareholders at the end of the reporting period was 14,389 [2]
美好医疗（301363）披露2025年三季度报告，10月21日股价下跌0.18%